Related Experiment Videos
Hemodynamic assessment of prenalterol: a cardioselective beta agonist in patients with imparied left ventricular
Insights
Prenalterol, a new beta agonist, improved heart contractility and reduced preload in patients with impaired left ventricular function. This cardioselective drug showed good tolerance without significant side effects, offering potential benefits for specific patient groups.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Patients with moderate to severe left ventricular dysfunction often face limited treatment options.
- Coronary heart disease and primary cardiomyopathy are leading causes of heart failure.
- Understanding the hemodynamic effects of novel therapeutic agents is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the hemodynamic effects of prenalterol, a novel cardioselective beta-1 agonist.
- To assess the impact of prenalterol on myocardial contractility, preload, and afterload in patients with impaired left ventricular function.
- To determine the safety and tolerability of prenalterol in this patient population.
Main Methods:
- A study involving 12 patients with moderate or severe left ventricular impairment.
- Hemodynamic parameters were measured before and after administration of prenalterol (up to 7 mg).
- Key metrics included left ventricular pressure, cardiac output, heart rate, and vascular resistance.
Main Results:
- Prenalterol significantly increased left ventricular pressure rise and circumferential fiber shortening, indicating enhanced contractility.
- The drug substantially decreased left ventricular end-diastolic pressure, mean pulmonary artery pressure, and pulmonary vascular resistance, suggesting reduced preload and afterload.
- Cardiac output increased in only 4 of 12 patients; heart rate and myocardial oxygen demand remained unchanged. No arrhythmogenic or other side effects were observed.
Conclusions:
- Prenalterol demonstrates a positive inotropic effect with good tolerance in patients with impaired left ventricular function.
- The drug effectively reduces left ventricular preload and pulmonary vascular resistance.
- Prenalterol may be particularly beneficial for patients with low sympathetic activity and hypotension; vasodilator therapy may be considered for others.
Abstract:
The hemodynamic effects of a new cardioselective beta agonist, prenalterol, were evaluated in 12 patients with moderate or severe impairment of left ventricular function due to coronary heart disease or primary cardiomyopathy. In doses up to 7 mg the drug led to a substantial increase of left ventricular pressure rise (+55%) and mean circumferential fiber shortening (+59%) and a decrease of left ventricular end-diastolic pressure (-52%), mean pulmonary artery pressure (-24%) and pulmonary vascular resistance (-37%) indicating augmented myocardial contractility and reduced left ventricular preload. Cardiac output was increased only in 4 of 12 patients, heart rate, left ventricular systolic and mean right atrial pressures and the pressure-rate product as an index for myocardial oxygen demand remained essentially unchanged. The same is true for stroke index, stroke work index, total peripheral resistance, left ventricular end-diastolic and end-systolic volume and ejection fraction. The positive inotropic effect was achieved with good tolerance and without arrhythmogenic or other side effects. Prenalterol may be especially useful in patients with low sympathetic activity and hypotension. In patients with diffuse congestive cardiomyopathy, high sympathetic activity, pronounced peripheral vasoconstriction and normal blood pressure, vasodilator therapy alone or in combination with prenalterol should be considered.